NBIX
NEUROCRINE BIOSCIENCES INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$159.76
−3.79%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$166.71
From 52W high−13.88%
Volume1.48M
Market cap$16.17B
P/E (TTM)22.9x
P/S (TTM)4.4x
Div yield—
Key dataNov 5, 2026
Open
$166.71
From 52W high
−13.88%
Volume
1.48M
Market cap
$16.17B
ValuationView details →
P/E (Fwd)
17.6x
EV/EBITDA
16.7x
P/E (TTM)
22.9x
RSI (14)
75.0
MomentumView details →
1D Return
−3.79%
YTD Return
+16.34%
SummaryUpdated Sep 1, 2026
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a San Diego-based biopharmaceutical company founded in 1992 and publicly traded since 1996. The company specializes in developing and commercializing treatments for neurological, endocrine, and psychiatric disorders. Originally focused on research and development, Neurocrine has evolved into a commercial-stage company with multiple marketed products and a robust pipeline of investigational therapies. The company has established itself as a leader in movement disorders and rare diseases, with its flagship product INGREZZA becoming a blockbuster treatment for tardive dyskinesia.
Similar companies
Latest newsMore news →
Neurocrine Biosciences announced survey findings that adults with tardive dyskinesia reported work or school disruptions declining from 57% before starting INGREZZA to 21% afterward, while average missed days per month fell from 5.6 to 2.0.1d agoNEUROCRINE BIOSCIENCES INC reported quarterly earnings of $3.29 per share, above the Zacks Consensus Estimate of $2.54 and compared with $2.04 per share a year earlier.4d agoNEUROCRINE BIOSCIENCES INC reported third-quarter 2026 revenue of $1.123 billion, net income of $206.5 million and diluted EPS of $1.96.4d ago